Omega Therapeutics/OMGA

$2.52

-5.79%
-
1D1W1MYTD1YMAX

About Omega Therapeutics

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.

Ticker

OMGA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mahesh Karande

Employees

93

Headquarters

Cambridge, United States

OMGA Metrics

BasicAdvanced
$147.54M
Market cap
-
P/E ratio
-$1.81
EPS
-
Beta
-
Dividend rate
$147.54M
$10.09
$1.30
502.44K
3.353
25.657
32.551
-55.62%
-118.82%
-64.61%
47.67
2.543
2.543
49.23%
15.67%

What the Analysts think about OMGA

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
369.44% upside
High $15.00
Low $9.00
$2.52
Current price
$11.83
Average price target

OMGA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,244.44% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$900K
12.5%
Net income
$-20.2M
-9.01%
Profit margin
-2,244.44%
-19.12%

OMGA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.50
-$0.54
-$0.40
-$0.37
-
Expected
-$0.60
-$0.51
-$0.53
-$0.45
-$0.32
Surprise
-16.19%
6.48%
-24.32%
-17.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Omega Therapeutics stock?

Omega Therapeutics (OMGA) has a market cap of $147.54M as of April 15, 2024.

What is the P/E ratio for Omega Therapeutics stock?

The price to earnings (P/E) ratio for Omega Therapeutics (OMGA) stock is 0 as of April 15, 2024.

Does Omega Therapeutics stock pay dividends?

No, Omega Therapeutics (OMGA) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Omega Therapeutics dividend payment date?

Omega Therapeutics (OMGA) stock does not pay dividends to its shareholders.

What is the beta indicator for Omega Therapeutics?

Omega Therapeutics (OMGA) does not currently have a Beta indicator.

What is the Omega Therapeutics stock price target?

The target price for Omega Therapeutics (OMGA) stock is $11.83, which is 369.44% above the current price of $2.52. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Omega Therapeutics stock

Buy or sell Omega Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing